Guerbet Group Overview
- Year Founded
-
1926
- Status
-
Public
- Employees
-
2,746
- Stock Symbol
-
GBT
- Investments
-
7
- Share Price
-
$7.22
- (As of Thursday Closing)
Guerbet Group General Information
Description
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
Contact Information
Website
www.guerbet.comCorporate Office
- 15 rue des Vanesses
- Zone Paris Nord II
- 93420 Villepinte
- France
Corporate Office
- 15 rue des Vanesses
- Zone Paris Nord II
- 93420 Villepinte
- France
Guerbet Group Stock Performance
As of 19-Nov-2026, Guerbet Group’s stock price is $7.22. Its current market cap is $90.8M with 12.6M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.22 | $7.24 | $6.51 - $21.12 | $90.8M | 12.6M | 11.2K | -$13.37 |
Guerbet Group Financials Summary
As of 30-Jun-2026, Guerbet Group has a trailing 12-month revenue of $923M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 461,383 | 557,177 | 671,060 | 568,072 |
| Revenue | 923,155 | 900,905 | 920,991 | 860,958 |
| EBITDA | 48,154 | (33,031) | 109,159 | 110,874 |
| Net Income | (163,962) | (122,198) | 17,404 | 25,825 |
| Total Assets | 1,113,112 | 1,092,414 | 1,079,337 | 1,133,302 |
| Total Debt | 548,440 | 518,266 | 411,155 | 427,522 |
Guerbet Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Guerbet Group Comparisons
Industry
Financing
Details
Guerbet Group Competitors (5)
One of Guerbet Group’s 5 competitors is GE HealthCare Technologies, a Corporation company based in Chicago, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GE HealthCare Technologies | Corporation | Chicago, IL | ||||
| Lantheus Holdings | Formerly PE-Backed | Bedford, MA | ||||
| NeuroLogica | Formerly VC-backed | Danvers, MA | ||||
| FluoroPharma | Formerly VC-backed | Montclair, NJ | ||||
| Analogic | Private Equity-Backed | Salem, NH |
Guerbet Group Patents
Guerbet Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026215310-A1 | Disubstituted macrocyclic ligands, complexes thereof and medical uses thereof | Pending | 08-Apr-2025 | ||
| WO-2026215340-A1 | Method for regioselective prepration of di- or tri-substituted macrocyclic ligands | Pending | 08-Apr-2025 | ||
| EP-4814865-A1 | A computer-implemented method for estimating the body composition of a patient from a restricted-field-of-view medical image | Pending | 27-Mar-2025 | ||
| WO-2026202140-A1 | A computer-implemented method for estimating the body composition of a patient from a restricted-field-of-view medical image | Pending | 27-Mar-2025 | ||
| EP-4811287-A1 | A computer-implemented method for pairing anatomical entities of at least one patient on medical images | Pending | 21-Mar-2025 | G06T7/30 |
Guerbet Group Signals
Guerbet Group Investments & Acquisitions (7)
Guerbet Group’s most recent deal was a Merger/Acquisition with Intrasense. The deal was made on 05-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Intrasense | 05-Jun-2023 | Merger/Acquisition | Decision/Risk Analysis | ||
| Intrasense | 11-Jan-2023 | PIPE | Decision/Risk Analysis | ||
| Accurate Medical Therapeutics | 02-Aug-2018 | Merger/Acquisition | Surgical Devices | ||
| Occlugel (laboratory-stage technology) | 26-Apr-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Mallinckrodt (CMDS Business) | 27-Nov-2015 | Merger/Acquisition | Diagnostic Equipment |
Guerbet Group ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
19.67 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Supplies
Subindustry
of 60
Rank
Percentile
Guerbet Group Affiliates
Subsidiaries (6)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Guerbet France | Villepinte, France | 2012 | |
| Guerbet | Milan, Italy | 2011 | |
| Intrasense | Montpellier, France | 2004 | |
| Guerbet Laboratories | Solihull, United Kingdom | 1994 | |
| Medex Biomedical | Saint Priest, France | 1988 |
Guerbet Group FAQs
-
When was Guerbet Group founded?
Guerbet Group was founded in 1926.
-
Where is Guerbet Group headquartered?
Guerbet Group is headquartered in Villepinte, France.
-
What is the size of Guerbet Group?
Guerbet Group has 2,746 total employees.
-
What industry is Guerbet Group in?
Guerbet Group’s primary industry is Diagnostic Equipment.
-
Is Guerbet Group a private or public company?
Guerbet Group is a Public company.
-
What is Guerbet Group’s stock symbol?
The ticker symbol for Guerbet Group is GBT.
-
What is the current stock price of Guerbet Group?
As of 19-Nov-2026 the stock price of Guerbet Group is $7.22.
-
What is the current market cap of Guerbet Group?
The current market capitalization of Guerbet Group is $90.8M.
-
What is Guerbet Group’s current revenue?
The trailing twelve month revenue for Guerbet Group is $923M.
-
Who are Guerbet Group’s competitors?
GE HealthCare Technologies, Lantheus Holdings, NeuroLogica, FluoroPharma, and Analogic are competitors of Guerbet Group.
-
What is Guerbet Group’s annual earnings per share (EPS)?
Guerbet Group’s EPS for 12 months was -$13.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process